Acurx Pharmaceuticals
ACXP
18 hedge funds and large institutions have $1.32M invested in Acurx Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
38% more funds holding
Funds holding: 13 → 18 (+5)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
5.97% less ownership
Funds ownership: 12.73% → 6.75% (-6%)
87% less capital inflows, than outflows
Capital inflows: $176K | Capital outflows: $1.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36K |
| 2 |
Renaissance Technologies
New York
|
+$36K |
| 3 |
Morgan Stanley
New York
|
+$28.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.6K |
| 5 |
Two Sigma Securities
New York
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$1.3M |
| 2 |
Millennium Management
New York
|
-$5.2K |
| 3 |
BlackRock
New York
|
-$1.45K |
| 4 |
Salem Investment Counselors
Winston Salem,
North Carolina
|
-$265 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$153 |
ACXP Hedge Fund Activity: Q3 2023 in Review
18 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q3 2023, worth a combined $1.32M — down 67% from $3.94M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ACXP positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $36K. The largest seller was Armistice Capital, cutting an estimated $1.3M.
- 18 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q3 2023, up from 13 in Q2 2023.
- Funds reported $1.32M of Acurx Pharmaceuticals stock for Q3 2023, down 67% quarter-over-quarter.
- 7 funds opened new Acurx Pharmaceuticals positions in Q3 2023 and 2 closed out, a net change of +5 holders.
- The largest Acurx Pharmaceuticals buyer in Q3 2023 was Citadel Advisors, an estimated $36K added.
- The largest Acurx Pharmaceuticals seller in Q3 2023 was Armistice Capital, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2023.